• June 16-19, 2025
  • Boston Convention & Exhibition Center

Sessions

Loading

PlantPharm Biomed, Ltd

Monday, June 03, 2024
Company Presentation
Infectious Disease and Vaccines
Company Presentation Theater 2
PlantPharm Biomed’s objective is to become the leader in manufacturing of plant-grown vaccines within the next five years. The company employs gene-edited plants in lieu of traditional single cell fermentation systems to produce oral vaccines with significant competitive advantages over injected vaccines; including shelf-stable, oral dose forms avoiding cold-chain storage problems and hypodermic needles. Since the vaccine administration is oral rather than injected it is easier to administer and avoids shelf-life problems associated with liquid vaccines, particularly in countries with inadequate logistics. This means that the powerful oral dosage version of a vaccine can now be administered broadly in both developed and developing countries previously limited by local logistic barriers. PlantPharm Biomed’s Management Team are each experts in their respective fields of knowledge and proficient in optimizing the vaccine production capabilities of the oral vaccine platform.
PlantPharm Biomed, Ltd
Company Website: http://www.plantpharmbiomed.com
Lead Product in Development: Feed-based, oral SARS Cov-2 vaccine for wild animal populations,particularly white-tailed deer

Company HQ City

Delavan

Company HQ State

Wisconsin

Company HQ Country

United States

CEO/Top Company Official

Robert Britt

Development Phase of Primary Product

Pre-Clinical
Primary Speaker
Richard Matner, PhD
President and Chief Strategy Officer
PlantPharm Biomed, Ltd
Back to Session List

BIO DOUBLE HELIX SPONSORS

Thanks to our sponsors for supporting our mission to drive a revolution to cure patients, protect our climate, and nourish humanity.

Loading

BIO HELIX SPONSORS